Literature DB >> 25212255

Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia.

Dana Wetzel1, Beatrice U Mueller, Behrouz Mansouri Taleghani, Gabriela M Baerlocher, Katja Seipel, Kurt Leibundgut, Thomas Pabst.   

Abstract

Autologous stem cell transplantation (ASCT) is applied to consolidate first remission in patients with acute myeloid leukaemia (AML). However, outcome after ASCT widely varies among AML patients. We analyzed the prognostic significance of haematological recovery for neutrophils [absolute neutrophil count (ANC) >1·0 × 10(9) /l] and platelets (platelet count >20·0 × 10(9) /l), stratifying at day 20 after ASCT in 88 consecutive and homogeneously treated AML patients in first remission. We observed that patients with delayed recovery had better overall survival (OS; ANC: P < 0·0001 and platelets: P = 0·0062) and time to progression (TTP; ANC: P = 0·0003 and platelets: P = 0·0125). Delayed recovery was an independent marker for better OS and TTP in a multivariate analysis including age, gender, number of transfused CD34+ cells, cytogenetics, FLT3-internal tandem duplication and NPM1 mutation. Our results suggest that delayed neutrophil and platelet recovery is associated with longer OS and TTP in AML patients consolidated with ASCT in first remission.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  acute myeloid leukaemia; autologous transplant; prognosis; recovery; stem cell

Mesh:

Year:  2014        PMID: 25212255     DOI: 10.1111/bjh.13118

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia.

Authors:  Alvaro de Santiago de Benito; Barbara Jeker; Eva Gfeller; Naomi Porret; Yara Banz; Urban Novak; Ulrike Bacher; Thomas Pabst
Journal:  Haematologica       Date:  2019-05-23       Impact factor: 9.941

2.  Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML.

Authors:  Ekaterina Gurevich; Michael Hayoz; Yolanda Aebi; Carlo R Largiadèr; Behrouz Mansouri Taleghani; Ulrike Bacher; Thomas Pabst
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

3.  Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression.

Authors:  Audrie A Medina-Colorado; Elvia Y Osorio; Omar A Saldarriaga; Bruno L Travi; Fanping Kong; Heidi Spratt; Lynn Soong; Peter C Melby
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

4.  [Analyses of outcome and prognostic factors of adult acute myeloid leukemia patients received autologous hematopoietic stem cell transplantation].

Authors:  Y G Cao; E L Jiang; Y He; J L Wei; R L Zhang; Y Huang; D L Yang; Q L Ma; S Z Feng; M Z Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14

Review 5.  Autologous Transplantation for Older Adults with AML.

Authors:  Beatrice U Mueller; Katja Seipel; Ulrike Bacher; Thomas Pabst
Journal:  Cancers (Basel)       Date:  2018-09-19       Impact factor: 6.639

6.  Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients.

Authors:  Bianca R Schnell; Katja Seipel; Ulrike Bacher; Barbara Jeker; Beatrice U Mueller; Yara Banz; Urban Novak; Thomas Pabst
Journal:  Hemasphere       Date:  2019-03-20

7.  Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients.

Authors:  Evgenyi Shumilov; Urban Novak; Barbara Jeker; Behrouz Mansouri Taleghani; Ulrike Bacher; Thomas Pabst
Journal:  Hemasphere       Date:  2019-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.